Non-SARS, non-MERS human coronavirus infections and risk of Kawasaki disease: a meta-analysis

Pratap Kumar Patra*,1, Rashmi Ranjan Das2, Aaqib Zaffar Banday3, Mini Singh4, Kapil Goyal5, Ankur Kumar Jindal2 & Surjit Singh3

1Department of Pediatrics, All India Institute of Medical Sciences, Patna, 801507, India
2Department of Pediatrics, All India Institute of Medical Sciences, Bhubaneswar, 751019, India
3Department of Pediatrics, Allergy Immunology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, 160012, India
4Department of Virology, PGIMER, Chandigarh, 160012, India
5Author for correspondence: Tel.: +91 7766 932165; pratap.patra3@yahoo.co.in

Aim: To study the association between non-SARS, non-MERS human coronavirus (HCoV) infections and Kawasaki disease (KD).

Methods: Meta-analysis of observational studies published until 1 May 2021.

Results: Out of 571 papers retrieved through database search, 10 provided data of 17,732 children. Age ranged from 2 months–14.9 years with 66% being male and 71% being complete KD. Compared with controls, there was an increased risk of developing KD in those detected to have HCoV infection (OR: 2.3 [95% CI: 1.06–4.99]; p = 0.03). The GRADE evidence for all outcomes was of ‘low-certainty’.

Conclusion: A ‘low certainty’ of evidence suggests an increased risk of KD in children infected with HCoV. We need multi-center, prospective studies to support or refute this finding.

PROSPERO protocol registration: CRD42021251582.

First draft submitted: 16 July 2021; Accepted for publication: 1 November 2021; Published online: 26 November 2021

Keywords: coronavirus ● evidence-based medicine ● Kawasaki disease ● meta-analysis ● observational study ● systematic review

Kawasaki disease (KD) is a common childhood vasculitis whose etiology remains unknown [1]. A complex interplay of infectious agents and environmental factors in genetically predisposed individuals is believed to give rise to this disorder [2,3]. Many viral agents that enter the body through respiratory tract have been implicated in pathogenesis of KD. This is further supported by seasonal occurrence of KD in some countries [2,3]. Peak incidence of KD in Japan and USA is observed during winter/summer and spring/winter, respectively [2,3]. Viruses that may trigger KD include adenovirus, parvovirus, influenza and parainfluenza. However, it is not known whether there is a causal relationship between these agents and KD [2,3].

Human coronaviruses (HCoV) belong to Orthocoronavirinae subfamily of Coronaviridae family [4]. Of four subfamilies, two (alpha and beta) cause respiratory and gastrointestinal infections in humans. Four human coronaviruses (HCoV-HKU1, HCoV-OC43, HCoV-229E and HCoV-NL63) cause mild respiratory tract infection and are known as non-SARS (severe acute respiratory syndrome)/non-MERS (Middle East respiratory syndrome) HCoV. On the other hand, SARS-CoV-1/2 and MERS-CoV have been associated with life-threatening infections [4].

In recent times, there has been a spate of reports on KD/KD-like disease triggered by SARS-CoV-2, termed as pediatric multisystem syndrome temporally associated with SARS-CoV-2 in EU (PIMS-TS), and multisystem inflammatory syndrome children (MIS-C) in the USA [5–7]. However, the same phenomenon has been sparingly observed in north-east Asian countries, such as Japan, Korea and Taiwan, that have much higher incidence rates of KD. This has opened up a new debate regarding the putative role of HCoV infection in evolution of KD. Systematic and narrative reviews have analyzed the association between SARS-CoV-2 and KD/KD-like illnesses [8,9]. There is, however, no published systematic review or meta-analysis that has studied the association between HCoV

10.2217/fvl-2021-0176 © 2021 Future Medicine Ltd

Future Virol. (Epub ahead of print) ISSN 1746-0794
infection (non-SARS and non-MERS) and KD. We tried to find out if HCoV infection was increasing the risk of development of KD in children of all age groups.

**Materials & methods**
This systematic review protocol is registered at PROSPERO: CRD42021251582

**Types of studies**
Observational studies that aimed at studying the association of HCoV infection with KD in both community and hospital settings were included.

**Types of participants**
Children of all age groups/sexes were included.

**Types of exposure**
Participants in exposure group included those with HCoV infection (confirmed by either RT-PCR or serology) and KD. In control group, children had HCoV infection but no features of KD.

**Types of outcome measures**

*Primary*
- Risk of development of KD in those infected with HCoVs.

*Secondary*
- Risk of development of KD in those infected with different serotypes of HCoVs (e.g., HKU1, HCoV OC43, HCoV 229E and HCoV NL63).

**Search methodology**
The following databases were searched systematically from the year 1967 to 1 May 2021: PubMed/MEDLINE, Google Scholar, Embase and pre-print servers (medRxiv, bioRxiv, OSF preprints, Pre-prints.org). The PubMed/MEDLINE search strategy used the various MeSH and free text terms for 'coronavirus', 'coronavirinae', 'novel coronavirus', HCoV, SARS CoV-2, COVID-19, MERS-CoV, 'Kawasaki disease', 'Kawasaki syndrome', 'mucocutaneous lymph node syndrome', 'observational studies', 'children', 'pediatric', using the Boolean operators. No language restrictions were applied. The search results were reviewed to identify relevant studies.

**Data extraction**
The data were extracted by using a pre-designed data extraction form and tested *a priori*. We independently extracted the following information from each study: author, year, location (country), study design, setting (hospital or community), method of recruitment, inclusion criteria, risk of bias, participants (age, sex, sample size and diagnosis), exposure (type of viruses, methods employed for diagnosis and method of ascertainment), outcomes (outcome definition, valid unit of measurement, time points of collection and reporting), lost to follow up and miscellaneous data (key conclusions, references to other studies and additional data required).

**Assessment of risk of bias in the included studies**
We independently assessed quality by using the Newcastle–Ottawa scale (NOS) for observational studies [10]. It assesses the quality of studies under three major domains: selection of studies, comparability and outcome/exposure. Any disagreements were resolved by discussion.

**Dealing with missing data**
The missing data were described that included dropouts in selected studies. Difference in dropout rates may lead to biased estimates of the effect size. Furthermore, bias may arise if the reasons for dropouts vary across different groups in different studies.

**Data synthesis**
Data were analyzed using Review Manager (RevMan, v.5.3, The Cochrane Collaboration, Copenhagen, Denmark) [11]. Data from included studies were pooled and expressed as odds ratio (OR) with 95% CI. A p-value
Non-SARS, non-MERS human coronavirus infections and risk of Kawasaki disease Meta-Analysis

Records screened (n = 499)
Records identified through database searching (n = 571)
Records after duplicates removed (n = 72)
Records excluded: titles and abstracts not relevant (n = 488)
Records screened (n = 499)
Full-text articles assessed for eligibility (n = 11)
Full text excluded (n = 1): Duplicate study
Studies included in qualitative synthesis (n = 10)
Studies included in quantitative synthesis (meta-analysis) (n = 7)

Figure 1. PRISMA flow diagram.

< 0.05 was considered statistically significant. Inter-study heterogeneity was assessed by Cochrane’s Q ($\chi^2 p < 0.10$) and quantified by $I^2$. An $I^2 \geq 50\%$ indicated ‘substantial’ heterogeneity and $\geq 75\%$ indicated ‘considerable’ heterogeneity [12]. Causes of substantial or considerable heterogeneity were explored and, sensitivity and/or sub-group analyses were carried out where feasible. We used both random- and fixed-effect models to see any difference in pooled effect. We constructed the funnel plot from primary outcome to ascertain any publication bias [13].

Grade of evidence
We used GRADE Profiler software (v.3.2) to assess certainty of evidence [14]. The software uses five parameters for rating the certainty of evidence. The parameters used are risk of bias, inconsistency of results or unexplained heterogeneity, indirectness of evidence, imprecision of results and publication bias.

Results
Description of studies
Of 571 total citations retrieved, full text of 11 papers was assessed for eligibility, and one duplicate paper was excluded (Figure 1) [15]. Of the remaining 10 eligible studies (17,732 children), we were able to do a meta-analysis of seven studies including 17,615 children (cases: 555; controls: 17,060) (Table 1). Age range of included children was 0.2–14.9 years, 66% were male and 71% had classic KD. Eight studies were case-control studies [16–23] and two were prospective studies [24,25]. The studies had been conducted in the following countries: USA (n = 5), Japan (n = 2), Taiwan (n = 2), The Netherlands (n = 1) and Germany (n = 1). Two studies employed serology (antibody assay) and immunofluorescence for diagnosis of HCoV infection, whereas the rest employed viral detection (RT-
| Study (year), country | Study design, study period | Sample size (n), age and sex of children | Characteristic of cases | Characteristic of controls | Diagnostic method employed | Associated serotypes | Time from onset of symptom to obtain sample | Additional comments | Ref. |
|----------------------|---------------------------|------------------------------------------|------------------------|---------------------------|--------------------------|---------------------|------------------------------------------|---------------------|-----|
| Esper et al. (2005), USA (single center) | Case-control study, from 2001 to 2004 | n = 33 (case: 11; control: 22). Mean age (months) = case 24.4; control 23.7. Male = 9 (82%) cases | Children <5 years and report negative for RSV, influenza viruses, parainfluenza viruses and adenovirus by direct fluorescent antibody assay | For each case KD case, 2 matched controls – the first 2 children with age difference <6 months from that of the cases | RT-PCR of respiratory specimen | New haven coronavirus | Median (range) days = 5 (4–13) | 53 children had KD, but 11 included as their respiratory specimen was available (attrition rate = 80%). Complete KD in 10 (91%) cases | [15] |
| Belay et al. (2006), USA (single center) | Case-control study, 1999 | n = 16 (case: 10; control: 6). Median age (year) = case (3.6) and control (3.3) Male = not mentioned | Cases were recruited from another study designed to look for link between KD and Chlamydia pneumoniae | Family members of KD patients and age-matched children attending outpatient clinics for well child visits | RT-PCR of pharyngeal specimen | HCoV-NL63 | <10 days in 6 children, and in rest 4 children on days 11, 15, 16 and 37 | 13 children had KD, but 10 included as their specimen was available (attrition rate = 23%). Complete KD cases not mentioned | [18] |
| Dominguez et al. (2006), USA (single center) | Case-control study, from 2004 to 2005 | n = 78 (case: 26; control: 52). Mean age (months) = case (46.2) and control (40.1) Male = 22 (85%) cases | Children <5 years and report negative for RSV, influenza viruses, parainfluenza viruses and adenovirus by direct fluorescent antibody assay | For each case KD case, 2 matched controls – the first 2 children with age difference <6 months from that of the cases | RT-PCR of nasopharyngeal specimen for HCoV-NL63 only | HCoV-NL63 | Mean (range) days = 8.8 (4-23) | 30 children had KD, but 26 included as their respiratory specimen was available (attrition rate = 13%). Complete KD in 20 (77%) cases | [21] |
| Lehmann et al. (2009), Germany (single center) | Case-control study, from 2006 to 2008 | n = 54 (case: 21; control: 33). Mean age (year) = case (4.5) and control (5.2) Male = 15 (71%) cases | Children fulfilling criteria of both complete and incomplete KD were enrolled | Not described | Serological assay (IgM, IgG, IgA) by a novel line-immunoassay | HCoV-NL63 | Mean (range) days = 5.5 (3–10) | No attrition. Complete KD in 12 (57%) cases | [20] |
| Chang et al. (2014), Taiwan (multi-center) | Case-control study, from 2004 to 2010 | n = 452 (case: 226; control: 226). Mean age (year) = case (2.0) and control (2.0). Male = 133 (58%) cases | Children fulfilling criteria of KD were enrolled | Age- and sex-matched children who did not have preceding illness for the 2 weeks prior to enrolment | RT-PCR and viral isolation of throat and naso-pharyngeal specimen | HCoV-NL63 HCoV-229E | Mean (SD) days = 7.5 (2.4) | No attrition. Complete KD cases not mentioned | [22] |
| Shirato et al. (2014), Japan (single center) | Case-control study, from 2001 to 2002 | n = 134 (case: 30; control: 104). Mean age (year) = case (2.3) and control (2.3). Male = 20 (67%) cases | Children fulfilling criteria of KD were enrolled | Age- and sex-matched healthy children | Serological assay (immunofluorescence and viral neutralization) | HCoV-NL63 HCoV-229E | Mean (range) days = 4.5 (1–7) | No attrition. Complete KD cases not mentioned | [19] |

KD: Kawasaki disease; N/A: Not applicable; RT-PCR: Real-time polymerase chain reaction; RSV: Respiratory syncytial virus; SD: Standard deviation.
Table 1. Characteristics of included studies (cont.).

| Study (year), country | Study design, study period | Sample size (n), age and sex of children | Characteristic of cases | Characteristic of controls | Diagnostic method employed | Associated serotypes | Time from onset of symptom to obtain sample | Additional comments |
|-----------------------|----------------------------|----------------------------------------|------------------------|---------------------------|---------------------------|-------------------|--------------------------------------------|---------------------|
| Turnier et al. (2015), USA (single center) | Case-control study, from 2009 to 2013 | n = 16,607 (case: 192; control: 16,415). Mean age (years) = case (2.9) and control (not mentioned). Male = 111 (58%) cases | Children fulfilling criteria of KD were enrolled | Those with available naso-pharyngeal specimen during the study period | RT-PCR of naso-pharyngeal specimen | HCoV-NL63, HCoV-229E, HCoV-OC43 | Median (range) days = 6 (5–8) | 222 children had KD, but 192 included as their respiratory specimen was available (attrition rate = 14%). Complete KD in 132 (78%) cases |
| Shimizu et al. (2005), USA and The Netherlands (multi-center) | Prospective study, from 2000 to 2005 | n = 48. Age = 2 months to 10 years. Male = 42 (88%) | Children fulfilling criteria of KD were enrolled | N/A | RT-PCR of throat and naso-pharyngeal specimen | HCoV-NL63 | Median (range) days = 7 (3–15) | Only 1 patient was positive for HCoV. No attrition. Complete KD cases not mentioned |
| Chang et al. (2006), Taiwan (multi-center) | Prospective study, from 2004 to 2005 | n = 53. Mean age (mean) = 2.3 years. Male = 27 (51%) | Children fulfilling criteria of complete and incomplete KD were enrolled | N/A | RT-PCR of throat, rectal and naso-pharyngeal specimen | HCoV-NL63 | M (d) days = 8.2 (2.8) | None of the patients was positive for HCoV. No attrition. Complete KD in 52 (98%) cases |
| Ebihara et al. (2005), Japan | Case-control study, from 2002 to May 2003 | n = 19 Mean Age = 22.6 months 4 months to 5 years | Children with KD were included | 208 children with respiratory tract infection | RT-PCR of napopharyngeal sample | HCoV-NL63 | Within 7 days | None of the patient with KD had HCoV. No mention about complete or incomplete KD |

KD: Kawasaki disease; N/A: Not applicable; RT-PCR: Real-time polymerase chain reaction; RSV: Respiratory syncytial virus; SD: Standard deviation.
### Table 2. Risk of bias (RoB) table.

| Study (year)       | Selection | Comparability | Exposure | Total |
|--------------------|-----------|---------------|----------|-------|
|                    | Is the case definition adequate? | Representativeness of the cases | Selection of controls | Definition of controls | Comparability of cases and controls on the basis of the design or analysis | Ascertainment of exposure | Same method of ascertainment for cases and controls | Nonresponse rate |
| Belay et al. (2005)| ***       | *             | **       |       |******|
| Chang et al. (2014)| ***       | *             | ***      |       |******|
| Dominguez et al. (2006)| ***     | *             | **       |       |******|
| Ebihara et al. (2005)| *       | *             | **       |       |******|
| Esper et al. (2005)| ***       | *             | **       |       |******|
| Shirato et al. (2014)| **     | *             | **       |       |******|
| Turnier et al. (2015)| **     | *             | **       |       |****  |
| Lehmann et al. (2009)| **     | *             | **       |       |****  |

This form has been designed to assess case control studies based on: (1) Selection of subjects (maximum of 4 stars were given one against each item); (2) Selection of controls (maximum of 2 stars were given) and (3) Assessment of exposure (maximum of 3 stars were given one against each numbered item).

PCR and/or culture) method [20,21]. Respiratory samples (from nose, nasopharynx or throat) were used by studies that used viral detection methods. Different studies have assessed the association of different serotypes of HCoVs with KD, and details are depicted in Table 1.

### Risk of bias in included studies

None of the studies was having a risk of bias in selection of cases, but four were at a high risk of bias for selection of controls [17,18,20,21]. Two studies were at high risk of bias for comparability of cases and controls [18,21]. All studies were having a low risk of bias for exposure parameters (Table 2).

### Effect of exposures

#### Primary outcome

Risk of development of KD in those infected with novel HCoV

Overall analysis: Seven studies were able to contribute data to the pooled analysis. Both fixed- and random-effect models were employed to see whether the findings were significant or not, as significant heterogeneity was noted among included studies ($I^2 = 58\%$; $p = 0.03$). There was an increased risk (odds) of developing KD in those detected to have infection with HCoV as found in both the models (random-effect model: OR: 2.3 [95% CI: 1.06–4.99]; $p = 0.03$ [Figure 2]; and fixed-effect model: OR: 2.16 [95% CI: 1.47–3.15]; $p = <0.0001$).

Sensitivity analysis: We did sensitivity analysis as one small study was contributing to the heterogeneity [16]. The pooled data showed decreased heterogeneity (21%) with an increased risk (odds) of developing KD in those detected to have infection with HCoV [OR: 1.86 (95% CI: 1.24 to 2.77); $p = <0.002$].

Subgroup analysis: we separately analyzed studies employing different diagnostic methods for HCoV (RT-PCR/viral detection or antibody assay). Overall analysis was not significant for studies employing either RT-PCR/viral detection (OR: 3.22 [95% CI: 0.79 to 13.08]; $p = 0.1$) or antibody assay (OR: 1.75 [95% CI: 0.96 to 3.18]; $p = 0.07$). As there was significant heterogeneity among studies, we did sensitivity analysis by removing one study [16]. Pooled data was significant without any remarkable heterogeneity (OR 1.96 [95% CI: 1.15 to 3.33]; $p = 0.01$).
Non-SARS, non-MERS human coronavirus infections and risk of Kawasaki disease

Meta-Analysis

Chang (2014)
Dominguez (2006)
Ebihara (2005)
Esper (2005)
Lehmann (2009)
Shirato (2014)
Turnier (2015)

Total (95% Cl)

Total events

Heterogeneity: Tau² = 0.54; Chi² = 14.43; df = 6 (p = 0.03); l² = 58%
Test for overall effect: Z = 2.12 (p = 0.03)

| Study or subgroup | Kawasaki disease | Control | Weight (%) | Odds ratio M-H, random, 95% CI |
|------------------|------------------|---------|------------|--------------------------------|
| Chang (2014)     | 16               | 2       | 226        | 100.0 8.53 [1.94, 37.56]       |
| Dominguez (2006) | 2                | 26      | 4          | 52    1.00 [0.17, 5.85]         |
| Ebihara (2005)   | 0                | 19      | 5          | 208   0.95 [0.05, 17.80]       |
| Esper (2005)     | 8                | 11      | 1          | 22    56.00 [5.05, 620.52]     |
| Lehmann (2009)   | 5                | 21      | 6          | 33    1.41 [0.37, 5.36]        |
| Shirato (2014)   | 25               | 60      | 29         | 104   1.85 [0.95, 3.61]        |
| Turnier (2015)   | 7                | 192     | 512        | 16415 1.18 [0.55, 2.51]       |
| **Total (95% Cl)**| **555**         | **17060**| **100.0**  | **2.30 [1.06, 4.99]**         |

| Total events | 63 | 559 |

Heterogeneity: Tau² = 0.54; Chi² = 14.43; df = 6 (p = 0.03); l² = 58%
Test for overall effect: Z = 2.12 (p = 0.03)

Figure 2. Primary outcome (odds of developing Kawasaki disease after infection with human coronavirus.

Secondary outcome
Risk of development of KD in those infected with different serotypes of HCoV
We separately analyzed data from included studies that reported different serotypes of HCoV (NL63, OC43, 229E). However, none of the serotypes was individually associated with risk of development of KD.

Publication Bias
Funnel plot was asymmetrical showing publication bias (Figure 3).

Grade (certainty) of evidence
Evidence generated was of ‘low certainty’ for all outcomes (primary and secondary). Likely reasons were heterogeneity among studies, poor methodological design and selective outcome reporting. A detailed analysis of the summary of evidence for primary outcome is provided in Table 3.
Table 3. GRADE table. Association of novel human coronavirus compared with no human coronavirus in children with Kawasaki disease.

| Outcomes                              | Patient or population: children with Kawasaki disease | Settings: community and Hospital | Exposure: HCoV | Comparison: No HCoV | Outcomes Illustrative comparative risks† (95% CI) | Relative effect (95% CI) | Number of participants (studies) | Certainty of the evidence (GRADE) |
|---------------------------------------|------------------------------------------------------|---------------------------------|----------------|---------------------|-------------------------------------------------|--------------------------|----------------------------------|----------------------------------|
| Association of HCoV with KD (all study data) | Study population                                    | OR: 2.3 (1.06–4.99)           | 17,615 (7 studies) | ⊕                   | Low‡, §, ¶                                            |
| Assumed risk                          | No coronavirus                                       | 32 per 1000                    | 81 per 1000 (34–179) |
| Corresponding risk                    | Coronavirus                                           | OR: 1.86 (1.24–277)           | 17,582 (6 studies) | ⊕⊕                   | Low‡, §, ¶                                            |
| Association of HCoV with KD (sensitive analysis) | Study population                                    | OR: 2.3 (1.06–4.99)           | 17,615 (7 studies) | ⊕                   | Low‡, §, ¶                                            |
| Assumed risk                          | No coronavirus                                       | 32 per 1000                    | 81 per 1000 (34–179) |
| Corresponding risk                    | Coronavirus                                           | OR: 1.86 (1.24–277)           | 17,582 (6 studies) | ⊕⊕                   | Low‡, §, ¶                                            |

GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
†The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
‡Case-control design of included studies.
§Significant statistical heterogeneity.
¶Asymmetry in funnel plot noted.
KD: Kawasaki disease; OR: Odds ratio.

**Discussion**

**Summary of evidence**

After an extensive search of the literature, we included ten studies with data of 17,732 children. As compared with controls, those having documented infection with HCoV were at a higher risk of developing KD. No particular serotype of HCoV was found to be associated with this increased risk. The evidence, however, is of ‘low certainty’.

In a case-control study published in 2005, Esper et al. first demonstrated the association between HCoV infection and KD [16]. Chang et al. confirmed this association in 2014 [23]. However, further case-control studies failed to replicate this association [17,20,21] which was likely due to relatively small sample sizes in the two older studies. Of the ten studies included in the present review, eight used RT-PCR for detection of HCoV, and two used serological assays. Use of serological assays may have been the reason for low detection rates of HCoV in these studies, as sensitivity of serological assays is lower than RT-PCR. Furthermore, there is a significant variability among studies based upon the interval between diagnosis of KD and RT-PCR testing for HCoV infection. Additionally, only a few studies have documented presence of concomitant respiratory symptoms (due to HCoV infection) and occurrence of KD.

In the present meta-analysis, we have analyzed the association of HCoV infections with KD. This has not been evaluated comprehensively to date. Recognition of association between HCoV with KD predates the KD or KD-like illnesses (in the form of multisystem inflammatory syndrome in children) seen in the ongoing SARS-CoV-2 pandemic by about a decade and a half. KD, KD-like illness (MIS-C/PIMS-TS) and severe COVID-19 infection induced vasculitis represent a similar disease spectrum characterized by a dysregulated immune response. It suggests that SARS-CoV-2 may just represent a ‘new kid on the block’ of various coronavirus infections associated with KD. In fact, KD has also been reported in association with the H1N1-pdm09 influenza infection that resulted in a pandemic a decade ago [26]. Besides, several other infectious illnesses have also been associated with KD [2]. Hence, there is a distinct possibility that there may be a surge in cases of KD or KD-like illnesses in future pandemics as well.

Exact etiology of KD remains an enigma. Many infectious illnesses can trigger KD in a genetically susceptible host. Of the various microbial agents, respiratory viruses have come up as the most important triggers for KD [2]. Causality has not been proven for any of the associated infectious agents to date, although, a KD-specific RNA respiratory virus has been postulated to exist based largely on autopsy studies [27]. Epidemiological profile of KD also favors the theory of an infectious trigger as it is predominantly seen in children below 5 years, is associated...
with seasonal clustering of cases with occasional epidemics, and the clinical features (such as fever, rash, cervical lymphadenopathy) mimic an infectious disorder.

It is plausible that HCoV infections may trigger KD illness in susceptible individuals. A number of genetic polymorphisms have been associated with an increased risk of developing KD in certain populations. Variability in HCoV-associated KD in different studies can therefore be easily explained by genetic differences among study populations [28]. It is possible that HCoV may be a risk factor for KD in populations with certain polymorphism(s) and not in others.

The exact pathogenesis of KD following HCoV infection is poorly understood and multifactorial. Endothelial dysfunction or inflammation is the hallmark of both KD and KD-like conditions that follow HCoV and SARS-CoV2 infection. HCoV has spike like protein that binds to angiotensin converting enzyme 2 (ACE2) receptors on surface of the target cell. A systematic review and meta-analysis have documented a significant risk of KD with ACE2 polymorphism [29]. Additionally, ACE2 polymorphisms have also been associated with other systemic vasculitides. SARS-CoV-2 has been shown to modulate ACE2 expression resulting with elevated TNF-α production [30]. Thus, modulation of ACE2 expression as a result of coronavirus infection or genetic polymorphisms may be one of the unifying pathogenetic mechanisms between the KD/KD-like illnesses following coronavirus infection and KD not associated with coronavirus infection.

Strengths & limitations
A comprehensive literature search, robust analysis and grading of evidence are strengths of the present review. Inclusion of only retrospective studies into the pooled analysis is a limitation (albeit unavoidable) of our review as the small sample size and retrospective nature may have introduced bias to overall estimate of results. Another limitation is that only three authors were involved in search methodology, risk of bias assessment and data extraction. This overlapping role might have introduced some bias in the review process. Furthermore, all studies were hospital based and were conducted mostly in developed countries. Hence, it may not be prudent to extrapolate the findings of this meta-analysis to the community at large.

Conclusion
A 'low certainty' of evidence suggests an increased risk of KD in children infected with HCoV. We need multi-center, prospective studies to support or refute this finding. The findings will be of great public health importance as KD/KD-like illnesses are closely associated with SARS-CoV-2 pandemic.

Future perspective
There should be elucidation of actual link between Kawasaki disease, and human coronaviruses (both SARS and non-SARS) at molecular level so that targeted therapy can develop as a form of prophylaxis.

Summary points
- Many studies have analyzed the association between SARS-CoV-2 and Kawasaki disease (KD)/KD-like illnesses with conflicting results, however, systematic review(s) or meta-analyses that have studied the association between human coronavirus (HCoV) infection (non-SARS and non-MERS) and KD are lacking.
- We included data of 17,732 children from ten observational studies, there was an increased risk (odds) of developing KD in those detected to have infection with HCoV (random-effect model: OR [odds ratio]: 2.3 [95% CI: 1.06–4.99]; fixed-effect model: OR: 2.16 [95% CI: 1.47–3.15]).
- None of the HCoV serotype was individually associated with risk of development of KD.
- 'Low certainty' evidence suggests an increased risk of KD in children infected with HCoV. Likely reasons were heterogeneity among studies, poor methodological design and selective outcome reporting.
- Publication bias was noted among the published studies.
- We need multi-center, prospective studies to support or refute this finding. The findings will be of great public health importance as KD/KD-like illnesses are closely associated with SARS-CoV-2 pandemic.

Author contributions
PK Patra: Concept, writing of initial draft and revision of manuscript; RR Das: Writing of initial draft of manuscript, statistical analysis, writing of initial draft and revision of manuscript; AZ Banday: Literature search and revision of manuscript; MP Singh: Writing of initial draft and revision of manuscript; K Goyal: Writing of initial draft and revision of manuscript; AK Jindal: Screening, data management and revision of the manuscript; S Singh: Revision of manuscript, overall supervision. All the authors have approved the final submitted version of the manuscript. PK Patra will act as guarantor.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.

References
1. Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat. Rev. Rheumatol. 16(7), 391–405 (2020).
2. Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. Front. Pediatr. 6, 374 (2018).
3. Yim D, Curtis N, Cheung M, Burgner D. Update on Kawasaki disease: epidemiology, aetiology and pathogenesis. J. Paediatr. Child Health 49(9), 704–708 (2013).
4. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17(3), 181–192 (2019).
5. Riollano-Cruz M, Akkoyun E, Briceno-Brito E et al. Multisystem inflammatory syndrome in children related to COVID-19: a New York city experience. J. Med. Virol. 93(1), 424–433 (2021).
6. Toubiana J, Poirault C, Corsia A et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. BMJ 369, m2094 (2020).
7. Bassareo PP. Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the United Kingdom and Ireland: what is new? Lancet. Reg. Health. Eur. 3, 100090 (2021).
8. Gonçalves LF, Gonzales AI, Patatt FSA, de Paiva KM, Haas P. Kawasaki and COVID-19 disease in children: a systematic review. Rev. Assoc. Medica. Bras (1992). 66(Suppl. 2), 136–142 (2020).
9. Mardi P, Esmaeili M, Iravani P, Abdar ME, Pourrostami K, Qorbani M. Characteristics of children With Kawasaki disease-like signs in COVID-19 pandemic: a systematic review. Front. Pediatr. 9, 625377 (2021).
10. Wells GA, Shea B, O’Connell D et al. The Newcastle-Ottawa quality assessment scale: case control studies. (2021).
11. The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.3. The Nordic Cochrane Centre, Copenhagen, Denmark (2014).
12. Higgins JPT, Green S. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions Version5.0.0. (2008). www.cochrane-handbook.org
13. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304), 101–105 (2001).
14. Schünemann H, Brozek J, Guyatt G, Oxman A. The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations. (2013). guidelinedevelopment.org/handbook
15. Baker SC, Shimizu C, Shike H et al. Human coronavirus-NL63 infection is not associated with acute Kawasaki disease. Adv. Exp. Med. Biol. 581, 523–526 (2006).
16. Esparza F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J. Infect. Dis. 191(4), 499–502 (2005).
17. Ebihara T, Endo R, Ma X, Ishiguro N, Kidota H. Lack of association between New Haven coronavirus and Kawasaki disease. J. Infect. Dis. 192(2), 351–352 (2005).
18. Turnier JL, Anderson MS, Heizer HR, Jone P-N, Głowę MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatr 136(3), e609–e614 (2015).
19. Belay ED, Erdman DD, Anderson LJ et al. Kawasaki disease and human coronavirus. J. Infect. Dis. 192(2), 352–353 (2005).
20. Shirato K, Imada Y, Kawase M, Nakagaki K, Matsuyama S, Taguchi F. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J. Med. Virol. 86(12), 2146–2153 (2014).
21. Lehmann C, Klar R, Lindner J, Lindner P, Wolf H, Gerling S. Kawasaki disease lacks association with human coronavirus NL63 and human bocavirus. Pediatr. Infect. Dis. J. 28(6), 555–558 (2009).
22. Dominguez SR, Anderson MS, Głowę MP, Robinson CC, Holmes KV. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki disease. J. Infect. Dis. 194(12), 1697–1701 (2006).
23. Chang LY, Lu CY, Shao PL et al. Viral infections associated with Kawasaki disease. J. Formos. Med. Assoc. 113(3), 148–154 (2014).
24. Chang LY, Chiang BL, Kao CL et al. Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. J. Infect. Dis. 193(2), 283–286 (2006).
25. Shimizu C, Shike H, Baker SC et al. Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease. J. Infect. Dis. 192(10), 1767–1771 (2005).
26. Banday AZ, Arul A, Vignesh P, Singh MP, Goyal K, Singh S. Kawasaki disease and influenza – new lessons from old associations. *Clin. Rheumatol.* 40(7), 2991–2999 (2021).

27. Rowley AH, Baker SC, Shulman ST et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. *J. Infect. Dis.* 203(7), 1021–1030 (2011).

28. Kumrah R, Vignesh P, Rawat A, Singh S. Immunogenetics of Kawasaki disease. *Clin. Rev. Allergy Immunol.* 59(1), 122–139 (2020).

29. Pan Y, Lu H. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Kawasaki disease: a meta-analysis. *Afr. Health. Sci.* 17(4), 991–999 (2017).

30. Haga S, Yamamoto N, Nakai-Murakami C et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. *Proc. Natl. Acad. Sci. USA* 105(22), 7809–7814 (2008).